Friday, 23 Aug 2019

You are here

Enbrel Patent Battle Won by Amgen

The ugly, legal, financial underbelly of US biosimilar drug development showed up in court last Friday, when a U.S. judge upheld two of Amgen's patents for Enbrel, thwarting a legal challenge by Novartis/Sandoz over its etanercept-szzs biosimilar, Erelzi. 

Sandoz won FDA approval for their etanercept biosimilar in 2016, but has not been able to market Erelzi because of Amgen’s extended patent protection (till 2029).

Although Enbrel sales have dropped in recent years, it is still a blockbuster biologic with U.S. sales of $4.8 billion last year.  

U.S. District Judge Claire Cecchi in Newark, New Jersey, rejected arguments by Novartis’ Sandoz unit that the patents covering Enbrel’s active ingredient until 2029 should not have been granted because their concepts were already contained in previous patents.

Novartis said it would appeal the ruling to the United States Court of Appeals for the Federal Circuit. 

“Sandoz respectfully disagrees with the Court’s ruling, which prevents us from launching an additional treatment option for patients with autoimmune and inflammatory diseases,” said Carol Lynch, President of Sandoz US and Head of North America. “Valid intellectual property should be respected, however, we continue to consider the patents in this case to be invalid. Amgen asserted two patents that it obtained from Roche, in what we believe is an attempt to extend its US compound patent protection for etanercept to 2029. We will appeal this decision, and look forward to presenting our case to the Federal Circuit and bringing Erelzi to US patients as soon as possible.”

While many U.S. regulators and politicians have called for the adoption and wider use of “biosimilar” versions of expensive biologic drugs, patent litigation and negotiations between companies have stalled the use of newer biosimilar versions of adalimumab and etanercept.  Only the infliximab biosimilars are currently marketed and in use. 

Amgen is also suing Samsung Bioepis over its Enbrel biosimilar. That litigation remains under way, an Amgen spokeswoman said on Friday. Officials at Samsung Bioepis did not immediately respond to a request for comment.

The economics of biologic drug use is such that they account for nearly 40% of U.S. prescription drug spending, and 70% of the growth in drug spending between 2010 and 2015.

Biosimilar

Reference

Pharma

Generic -suffix

Approved

Inflectra

Remicade

Celltrion

infliximab-dyyb

April 2016

Erelzi

Enbrel

Sandoz

etanercept-szzs

August 2016

Amjevita

Humira

Amgen

adalimumab-atto

Sept 2016

Renflexis

Remicade

Samsung

infliximab-abda

May  2017

Cyltezo

Humira

Boehringer

adalimumab-adbm

August 2017

Ixifi

Remicade

Pfizer

infliximab-abda

December 2017

Hyrimoz

Humira

Sandoz

adalimumab-adaz

October 2018

Eticovo

Enbrel

Samsung

etanercept-szzs

April 2019

Hadlima 

Humira

Samsung

adalimumab-bwwd

July 2019

 

 

Add new comment

More Like This

TNF Inhibitor and Biologic Induced Psoriasis

Analysis of RA patients in the German biologics register, RABBIT, shows an increased risk of psoriasis with TNF inhibitor (TNFi) compared to csDMARDs and other non-TNFi biologics. 

Among RABBIT RA patients without (n = 14,525) or with a history of psoriasis (n = 375) they assessed the risk of incident psoriasis or flare according to what biologic or csDMARD taken.

FDA Approves Cimzia for Non-Radiographic Axial Spondyloarthritis

The U.S. Food and Drug Administration today approved Cimzia (certolizumab pegol) injection for treatment of adults with a certain type of inflammatory arthritis called non-radiographic axial spondyloarthritis (nr-axSpA), with objective signs of inflammation. This is the first time that the FDA has approved a treatment for nr-axSpA.

Lower TNF Inhibitor Persistence in Spondylitis

A claims data analysis shows that only one-third of ankylosing spondylitis (AS) treated with tumor necrosis factor inhibitors (TNFi) therapy remain on their initial drug in the 2 years post initiation.

The Risk of Tuberculosis with TNF Inhibitors

A study from Turkey shows that among 2117 patients treated with a TNF inhibitor (TNFi) the risk of developing TB was 6 fold higher in those treated with a TNFi compared to non-users.

This retrospective cohort study included patients with rheumatoid arthritis (RA), ankylosing spondylitis, juvenile idiopathic arthritis or psoriatic arthritis (PsA) that treated with or without TNFI. The calculated the 2-year RR of TB after TNFi.

Higher Infection Rates for Infliximab in Psoriasis

A prospective study of psoriasis patients from the British Association of Dermatologists Biologic Interventions Register demonstrated that infliximab therapy yielded 2-3 times more serious infection than seen in those treated with non-biologic DMARDs or methotrexate (MTX).